Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible egfr tyrosine kinase inhibitors

Lorenza Landi, Marcello Tiseo, Rita Chiari, Serena Ricciardi, Elisa Rossi, Domenico Galetta, Silvia Novello, Michele Milella, Armida D'Incecco, Gabriele Minuti, Carmelo Tibaldi, Jessica Salvini, Francesco Facchinetti, Eva Regina Haspinger, Diego Cortinovis, Antonio Santo, Giuseppe Banna, Annamaria Catino, Matteo Giajlevra, Lucio CrinòFilippo De Marinis, Federico Cappuzzo

Research output: Contribution to journalArticlepeer-review

Abstract

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials and Methods We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and EGFR TKIs. Results A total of 96 individuals were included in the study. According to EGFR status, most patients (n = 63; 65.6%) harbored a deletion in exon 19, and de novo T790M mutation was detected in 2 cases (T790M and exon 19). Twenty-four (25%) patients underwent repeated biopsy immediately before starting afatinib and secondary T790M was detected in 8 (33%) samples. Among the 86 patients evaluable for efficacy, response rate was 11.6%, with a median progression free-survival (PFS) and overall survival (OS) of 3.9 and 7.3 months, respectively. No significant difference in PFS and OS was observed according to type of last therapy received before afatinib, type of EGFR mutation or adherence to Jackman criteria, and patients benefiting from afatinib therapy had longer PFS and OS (P

Original languageEnglish
Pages (from-to)411-417.e4
JournalClinical Lung Cancer
Volume15
Issue number6
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • Acquired resistance
  • Afatinib
  • Erlotinib
  • Gefitinib
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible egfr tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this